Twist Bioscience Corporation and Centogene N.V. announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and support diagnostics. Target enrichment panels enable more in-depth sequencing on target genes, reducing the need for comprehensive sequencing. This allows for more sensitive detection of target genetic sequences and provides higher confidence that variants will be detected, further driving the understanding of diseases and supporting healthcare professionals in providing precision medicine.

Labs and research institutions can purchase these ready-made panels to help accelerate their research, and also have the option of using CENTOGENE's CentoCloud® for the identification, prioritization, and classification of human genetic variants to expedite diagnostic analysis. All three new Alliance Panels are highly curated using the CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. Identified sequences are then synthesized by Twist as biotinylated capture probes which are compatible with Twist's library preparation solution and target enrichment workflows.

The panels offered through Twist will include: The Twist Alliance CNTG Exome Panel, which enables whole exome analysis of genetic markers relevant to rare diseases. The Twist Alliance CNTG Rare Disease Panel, which offers analysis of focused rare-disease-related sequences and The Twist Alliance CNTG Hereditary Oncology Panel, which enables the detection of biomarkers that indicate a high risk of developing cancer.